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Abstract
Despite effective chemotherapy to treat schistosome infections, re-infection rates are extremely high. Resistance to
reinfection can develop, however it typically takes several years following numerous rounds of treatment and re-infection,
and often develops in only a small cohort of individuals. Using a well-established and highly permissive mouse model, we
investigated whether immunoregulatory mechanisms influence the development of resistance. Following Praziquantel
(PZQ) treatment of S. mansoni infected mice we observed a significant and mixed anti-worm response, characterized by Th1,
Th2 and Th17 responses. Despite the elevated anti-worm response in PBMC’s, liver, spleen and mesenteric lymph nodes, this
did not confer any protection from a secondary challenge infection. Because a significant increase in IL-10-producing
CD4
+CD44
+CD25
+GITR
+ lymphocytes was observed, we hypothesised that IL-10 was obstructing the development of
resistance. Blockade of IL-10 combined with PZQ treatment afforded a greater than 50% reduction in parasite establishment
during reinfection, compared to PZQ treatment alone, indicating that IL-10 obstructs the development of acquired
resistance. Markedly enhanced Th1, Th2 and Th17 responses, worm-specific IgG1, IgG2b and IgE and circulating eosinophils
characterized the protection. This study demonstrates that blocking IL-10 signalling during PZQ treatment can facilitate the
development of protective immunity and provide a highly effective strategy to protect against reinfection with S. mansoni.
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Introduction
Despite inexpensive and effective chemotherapy, schistosomiasis
continues to plague sub-Saharan Africa, south-east Asia, south
America and areas of the Caribbean. This is due, in part, to rapid
re-infection rates following curative chemotherapy. Recent
estimates indicate that 200 million individuals are infected with
a further 700 million people at risk of infection [1]. Although
schistosomiasis research and control programs [2,3,4] are
attempting to increase the availability and variety of anti-
schistosomal drugs [5,6] (particularly following the emergence of
praziquantel (PZQ)-resistant parasites [7,8]) and develop novel
vaccines [9,10,11,12], additional approaches are required to
complement classical chemotherapy.
A central tenet of vaccine strategies for schistosomiasis is the
induction of immunity to infection and re-infection. Despite
significant work in this area over the last half century, the precise
mechanisms of resistance to re-infection continue to be debated.
Results from sufficiently powered longitudinal field studies suggest
that resistance to re-infection can develop naturally [13], but only
after multiple rounds of exposure, treatment, and re-infection
[14,15]. These observations have led to an age-dependent
resistance model [14,16], which has dominated the schistosomiasis
field for several decades. In this model, children ,15 years old are
highly susceptible to re-infection post-treatment, with a gradual
increase in resistance over time [16,17]. However, a recent study
by Karanja and colleagues[18] challenged this model and reported
that occupationally exposed individuals in Kenya fall into one of
three distinct groups; (1) immunologically resistant to re-infection
independent of age; (2) immunologically susceptible irrespective of
age; and (3) resistant to re-infection following multiple rounds of
treatment. This important study suggested that resistance to re-
infection could develop in response to curative chemotherapy and
thus may not be strictly age-dependent, but rather exposure-
dependent. It is worth noting however, that age and exposure are
themselves proportional to one another and closely related.
Many studies have reported correlations between immunolog-
ical responsiveness to schistosome antigens and protection from re-
infection, supporting an immunological mechanism of resistance
to re-infection. Karanja and colleagues [18] support this
hypothesis and implicated CD4
+T cells in the development of
resistance, loosely inferred from reduced resistance to schistosome
infection observed in HIV
+ patients with low CD4 counts. To
date, few reports have provided a detailed analysis of concurrent
immunological effector and regulatory responses that are induced
following PZQ treatment, either in humans or animal models. We
wondered whether activation of inappropriate ‘regulatory’ re-
sponses might be disrupting the development of resistance to re-
infection following curative chemotherapy. To address this
question, we conducted a detailed analysis of the immunological
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immunoregulatory responses in the highly permissive experimen-
tal mouse model of Schistosoma mansoni infection. In addition to
enhanced Th2 responses as previously reported[19,20], we
observed increased in anti-worm Th1 and Th17 responses two-
weeks after PZQ treatment. Despite the exaggerated anti-worm
responses in PZQ-treated mice, no resistance to a subsequent
challenge infection was observed. Using a bicistronic IL-10
gfp-
reporter mouse system, we identified increased populations of
CD4
+CD44
+CD25
+GITR
+IL-10
gfp+ cells in the blood, mesenteric
lymph nodes, spleen and liver of PZQ-treated and re-challenged
mice. These observations suggested that an effector or regulatory
population expressing IL-10 might be restricting the emergence of
immunity following PZQ treatment. To investigate this, we used
anti-IL-10R antibodies to block IL-10 signaling. Mice adminis-
tered anti-IL-10R antibodies during PZQ-treatment displayed a
greater than 50% reduction in worm burdens compared to control
mice. Taken together, these data indicate that IL-10 signaling
impedes the development of immunity to S. mansoni and suggests
that interfering with immunoregulatory mechanisms in combina-
tion with PZQ can accelerate resistance to re-infection in mice.
Methods
Animals
Six to eight week old female C57BL/6 and C57BL/6 Foxp3
gfp
reporter mice, originally provided by Bettelli and colleagues [21],
were maintained by Taconic farms. C57BL/6 IL-10
gfp ‘tiger’ mice
were kindly provided by Dr. Richard Flavell [22]. All animals were
housed under specific pathogen-free conditions at the National
Institutes of Health in an American Association for the
Accreditation of Laboratory Animal Care–approved facility. A
minimum of 7 mice were used in each experimental group unless
otherwise indicated.
Infections and reagents
Mice were infected percutaneously via the tail with 35 or 120
cercariae, as indicated, with a Puerto Rican strain of S. mansoni
(NMRI) obtained from Biomphalria glabrata snails (Biomedical
Research Institute). Where indicated, cercariae were attenuated
with 40 krad of gamma irradiation from a
137Cs source. Mice were
vaccinated by immersion of their tails in water containing
approximately 500 attenuated parasites for 40 minutes. SEA was
obtained from purified and homogenized S. mansoni eggs as
previously described [23]. Animals were perfused at sacrifice so
that worm burdens could be determined. Two 500 mg/kg doses of
Praziquantel (PZQ) (Sigma Aldrich, St. Louis, MO) were
administered in a Glycerol/Cremaphor EL emulsion to infected
mice at indicated times by oral gavage. One milligram of Anti-IL-
10R antibody was administered at the time of PZQ treatment
(week 6) followed by one more injection on week 7 and week 8.
Anti-IL-10RAb (Clone 1B1.3a, BioXCell, New Hampshire, USA)
reacts with CD210 (IL-10Ra) the IL-10-specific chain of the IL-
10R complex.
SWAP-specific recall responses in vitro
All in vitro cultures were performed in complete RPMI 1640
medium supplemented with penicillin (100 U/ml) Streptomycin
(100 mg/ml) (GIBCO) and glutamine (4 mM) (GIBCO), plus 10%
fetal calf serum (FCS) (GIBCO), unless otherwise stated. Single cell
suspensions from lymph nodes or spleens were incubated in
quadruplicate at 1610
6 cells/well of a round-bottomed 96 well
plate in a total of 200 mla t3 7 uC. Proliferation in response to
media (unstimulated control) SWAP antigen (10 mg/ml) or
Concanavalin A (1 mg/ml)(Mitogen, positive control) was mea-
sured by the addition of 1 mCi of [
3H] thymidine for the last
18 hours of a 72 hour incubation. Supernatants were collected,
after 54 hours of culture, and stored at -80uC for cytokine analysis.
[
3H]-thymidine incorporation was used as an indication of cellular
proliferation, with [
3H] Thymidine incorporation into cellular
DNA, captured on glass fiber filter mats (PerkinElmer/Wallac-
1450-421) coated with scintillator sheets (PerkinElmer/Wallac-
1450-411) and measured in a scintillation counter.
Polymorphonucelar cell (PMN) and Eosinophil Analysis
EDTA-treated blood was processed for automated counting
using Vista Analyzer (Siemens).
ELISA. Cytokines were measured by ELISA using Immulon
2HB plates (Thermo) and manufacturers guidelines. Paired
capture and detection antibodies from R&D for IL-17A, and
IFNc were used. Capture and detection antibodies for IL-4, IL-5
and IL-10 were purchased from BD Pharmingen. Serum IL-5 and
IFNc was measured using an in vivo cytokine capture assay
(IVCCA) as previously described [24]. ELISA’s plates were
washed with 0.05% Tween 20 in PBS (PBST) and blocked with
5% milk in PBST. Recombinant cytokine standards (R&D) were
used to assess quantity of cytokines in supernatants using a
standard curve, with OD acquired at 405 nm in an ELISA reader.
SWAP-specific IgE, IgG1 and IgG2a antibodies were
determined by ELISA. Serum samples were diluted in TBS/
Tween and wells washed between each incubation step with TBS/
Tween. Flat-bottomed 96 well plates were coated with 10 mg/ml
of SWAP diluted in carbonate buffer (0.1 mM NaHCO3, pH 8.2).
After washing, non-specific binding was blocked by incubating
wells with 5% BSA (Fraction V, Gibco) in carbonate buffer, for
2 hours at 37uC. Doubling dilutions of serum from 1:10 to 1:1280,
Author Summary
Schistosomes are zoonotic parasitic helminths that infect
hundreds of millions of people worldwide. Despite
effective chemotherapy, schistosomiasis- the disease
caused by these parasites, still plagues tropical regions
of the world. This is due, in part, to poor resistance to
reinfection resulting in high re-infection rates following
treatment. This lack of resistance is intriguing, as effective
treatment relies upon drug-induced parasite damage
combined with host immune mediated killing. Further-
more, it has been widely reported that post-treatment,
individuals develop and retain elevated levels of anti-
parasite immune responses. We therefore asked why
resistance to re-infection is so poor, despite the develop-
ment of significant anti-worm responses post-treatment. It
is essential that immune responses are controlled by
various immunosuppressive mechanisms to prevent im-
mune-mediated pathologies. However, a robust immuno-
regulatory response may obstruct the development of
protective immunity. Thus, a balanced immune response
providing a non-pathogenic yet effective immune re-
sponse may be required for the development of effective
resistance to reinfection. Understanding the immunolog-
ical mechanisms of resistance to re-infection and the role
of effector and regulatory responses may aid in the
development of more effective vaccines and treatment
strategies for schistosomaisis. This study suggests that
combining chemotherapy with drugs that block IL-10
might provide an improved strategy to elicit acquired
immunity to this parasite.
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overnight at 4uC. For measurement of SWAP-specific-IgE, IgG
was first depleted as SWAP-specific-IgG antibodies, which may be
in more than 100-fold excess to IgE antibodies, interfere with the
detection of SWAP-specific IgE. A 1:4 dilution of serum in PBS
was incubated overnight on a rotator at 4uC with protein-G bound
sepharose beads (Pharmacia Biotech) (85 ml, packed beads). IgG-
depleted serum was recovered by centrifugation, diluted in TBS/
Tween and added to SWAP-coated plates. Plates were incubated
with Biotinylated anti-mouse IgE (Clone R35 118, Pharmingen)
for 2 hours before Extravidin–alkaline phosphate (Sigma-Aldrich)
was added to the plate at 4 mg/ml for 1 hour at 37uC. Finally, p-
nitrophenyl substrate was added and the reaction was allowed to
develop before monitoring at 405 nm. For IgG1, HRP conjugated
anti-mouse IgG1 (BD PharMingen) was added at 1:2000 dilution,
HRP conjugated anti-m IgG2a (BD PharMingen) was used at
1:4000 dilution. Following incubation, 50 ml/well of ABTS
peroxidase substrate system (50-62-00, KPL) was added, left to
develop and monitored at 405 nm. Total IgE was measured with
anti-mouse IgE capture antibody (BD, clone R35-72) and
biotinylated anti-mouse IgE detection antibody (BD, clone R35-
118,), using a monoclonal IgE standard curve (BD, clone 27-74).
Flow cytometry
Cells were stained with antibodies diluted in PBS with 0.5%
BSA (Sigma-Aldrich) and 0.05% sodium azide (Sigma-Aldrich) for
20 minutes at 4uC. Surface molecule staining (CD3 (BD), CD4
(BD), CD44 (BD), CD25 (eBioscience), B220 (BD), GITR
(BioLegend) was carried out on freshly isolated cells. The
expression of surface molecules and intracellular molecules (IL-
10
gfp or foxp3
gfp) were analyzed on a BD LSR II flow cytometer
using FlowJo v.8 software (Tree Star).
Statistical analysis
Data sets were compared by Mann Whitney test using Prism
software v5. Differences were considered significant (*) at P ,
0.05.
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Animal Care and Use Committee
(ACUC) of the NIAID/NIH (protocol LPD 16E).
Results
Praziquantel (PZQ) treatment of S. mansoni infected mice
increases anti-worm immune responses
Praziquantel(PZQ)continues tobeoneofthemost effective,least
expensive and most readily available schistosomicides[5,6]. Effec-
tive removal of adult worms requires synergism between PZQ-
associated worm tegument damage [25,26] and immune-mediated
killing [27,28]. To determine the nature of the immune response
responsible for immune mediated killing, we measured anti-worm
responses 2 weeks post-PZQ treatment (Figure 1A). PZQ-
treatment was effective at eliminating adult worms (Figure 1B)
and led to a spike in weight-gain post treatment (Figure 1C).
Increased anti-worm specific proliferation was observed in circu-
lating PBMC’s, local draining mesenteric lymph nodes (m:LN) and
systemically in the spleen following PZQ-treatment (Figure 1D).
Anti-worm Th2 (IL-4 and IL-5) responses were evident in SWAP-
stimulated circulating leukocytes, m:LN and splenocytes
(Figure 1E) in addition to immunoregulatory IL-10. Similar to
observations made here in murine schistosomiasis, schistosome-
infected humanstreatedwith PZQ experience a gain in weight[29],
an increase in worm-specific cellular proliferation [30,31] and
increase in anti-worm Th2 responses [31]. Anti-worm Th1 (IFNc)
was only detected in the spleen, while evidence of a Th17 response
(IL-17A) was only detected in the local m:LN and in the PBMC’s of
PZQ-treated mice (Figure 1E). Thus, following PZQ-treatment,
anti-worm Th2, Th1 and Th17 responses were all increased, with
statistically significant increases of IL-5, IFNc, IL-17A and IL-10 in
various immunological compartments (Figure 1E). Anti-worm
IgG2a was also increased following PZQ treatment (Figure 1F)
with anti-worm IgG1 remaining unchanged and anti-worm IgE
undetectable (data not shown). Collectively these data indicate that
a mixed anti-worm cytokine, cellular and humoral immune
responses were enhanced following PZQ treatment.
Increased anti-worm responses post-PZQ fails to provide
resistance to re-infection
Two-weeks post PZQ treatment, when anti-worm immune
responses were significantly elevated, compared to infected,
untreated mice (Figure 1), we re-challenged mice with 120
cercariae to determine if the enhanced anti-worm response would
afford any protection against re-infection (Figure 2A). Compared
to challenged only (–/–/120) and PZQ-treated challenged only
control groups (–/PZQ/120), infected and PZQ-treated mice (35/
PZQ/120) did not display any protection from a challenge
infection (Figure 2B)[32–33], with similar total worm burden at
week 15 (7-weeks post challenge). PZQ-treated mice (35/PZQ/
120) mounted a greater systemic IL-5 and IFNc response
(Figure 2C) accompanied by elevated circulating polymorpho-
nuclear (PMN) cells but reduced eosinophils (Figure 2D),
compared to challenge only mice (–/–/120). To determine
whether specific anti-worm responses were intact, spleen and
mesenteric lymph node cells were re-stimulated with soluble worm
antigen (SWAP). Worm-specific IL-4, IL-5 and IFNc were
significantly elevated in the spleen of PZQ-treated mice compared
to challenge-only mice (–/–/120, Figure 2E) with a similar trend
observed in the m:LN’s (Figure 2F). IL-17A responses, however,
were undetectable in the spleen and present at low levels in the
m:LN (Figure 1E, 1F). Adult worm–specific (IgG1, IgG2b, IgE)
and total IgE antibody titers were significantly elevated in PZQ-
treated mice compared to challenge-only mice (Figure 2G).
However, despite the development of significantly increased
systemic cytokine responses, mobilization of granulocytes and
the maturation of worm-specific cytokine and antibody responses,
there was no resistance to re-infection.
Increased IL-10
+CD4
+CD44
+CD25
+GITR
+ cells post-PZQ
In addition to the effector arm of the immune response
(Figure 2), we analyzed the development of immunoregulatory
responses following PZQ-treatment and re-challenge. Using IL-
10
gfp reporter mice in conjunction with several immunoregulatory
co-receptors, we profiled the regulatory T cell responses. At the
time of re-challenge (week 8, data not shown) and at week 15, we
observed an expansion of IL-10-producing cells (Figure S1 and
Figure 3). Using multi-color flow cytometry, we identified a
major population of IL-10-producing cells within the CD4
+
lymphocyte population. We further delineated a sub-population of
CD4
+CD44
+CD25
+GITR
+ cells (R3, Figure 3), which were
increased proportionally (Figure 3A) and in total number
(Figure 3B) in the mesenteric lymph nodes, in addition to other
IL-10-producing populations within the CD4
+CD44
+CD25
–
GITR
+/– gates (R2, Figure 3). Similar IL-10-producing popula-
tions were observed in the liver, peripheral blood and spleen
Resistance to Re-Infection is Inhibited by IL-10
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significant increase in IL-10-prodcuing cells in PZQ-treated mice,
compared to challenge-only mice (Figure 3). Together with data
presented in figure 2, the increased effector responses (Figure 2)
appeared to be mirrored by a significant expansion of IL-10-
producing cells (Figure 3). Furthermore, we also observed a
Figure 1. Elevated anti-worm responses post PZQ treatment. C57BL/6 mice were infected with 35 cercariae before treatment with 2 doses of
PZQ at week 6. Mice were killed at week 8 for analysis. 10 mice per group were used. Data shown are from one of 3 experiments, with mean 6 SEM.
(A) Experimental model diagram. (B) Total worm numbers at week 8. 2-weeks post PZQ. (C) Weight change throughout 8-week period. (D) Tritiated
[H]
3 thymidine incorporation in peripheral blood-derived leukocytes, mesenteric lymph nodes and splenocytes following adult worm antigen re-
stimulation. (E) Cytokine secretions, measured by ELISA, from adult worm antigen re-stimulation, as in D. (F) Anti-worm antibody responses,
measured by ELISA.
doi:10.1371/journal.ppat.1002171.g001
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PLoS Pathogens | www.plospathogens.org 4 August 2011 | Volume 7 | Issue 8 | e1002171Figure 2. Comparable susceptibility to re-infection despite elevated anti-worm responses in PZQ-treated mice. C57BL/6 mice were
infected with 35 cercariae (35/–/–) before treatment with 2 doses of PZQ at week 6 (35/PZQ/–). Mice were re-challenged with 120 cercariae at week 8
(35/PZQ/120), 2-weeks post PZQ treatment and killed at week 15 for analysis. 7–10 mice per group were used. Data shown are from one of 3
experiments, with mean 6 SEM. (A) Experimental model diagram. (B)Total worm numbers at week 15. (C) Serum cytokines, IL-5 and IFNc. (D)
Circulating eosinophils and poly-morphonuclear cells. (E) Cytokine secretions, measured by ELISA, from adult worm antigen re-stimulated
splenocytes. (F) Cytokine secretions, measured by ELISA, from adult worm antigen re-stimulated mesenteric lymph node cells. (G) Anti-worm
antibody responses, measured by ELISA.
doi:10.1371/journal.ppat.1002171.g002
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+CD44
+CD25
+GITR
+IL-10gfp
+ cells in PZQ-treated mice. C57BL/6 mice were infected as in Figure 2, with cells isolated
from the mesenteric lymph nodes at necropsy. Cells were stained, as in methods and analyzed with FlowJo software. Data shown are mean 6 SEM
from one of 2 experiments, with 5 mice per group. (A) % of cells in CD4 gate. (B) Total number of cells in mesenteric lymph nodes (x10
3).
doi:10.1371/journal.ppat.1002171.g003
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spleen (Figure 4A) and m:LN (Figure 4B) of PZQ-treated mice.
The frequency of CD4
+CD25
+Foxp3
+ cells however did not
change significantly in any of the sites examined (Figure 4C),
neither were their differences in other inhibitory receptors BTLA,
PD1, CTLA-4, or LAG3 (data not shown). Thus, in addition to
the development of significant anti-worm Th1, Th2 and Th17-
associated effector responses in PZQ-treated mice (Figure 2), a
noteworthy increase in CD4
+CD44
+CD25
+GITR
+IL-10gfp
+ T
cells were also observed in similar immunological sites.
IL-10R blockade during PZQ treatment increases
resistance to re-infection
We hypothesized that the lack of resistance to re-infection, in
the face of significant anti-worm immune responses, was due to
increased IL-10, which could be inhibiting protective anti-worm
Figure 4. Elevated worm-specific IL-10 from spleen and mesenteric lymphnodes, with unchanged Foxp3+ cells. C57BL/6 mice were
infected as in Figure 2, with cells recovered at necropsy. Data shown are mean 6 SEM from one of 2 experiments, with 5 mice per group. (A) IL-10
secretions, measured by ELISA, from adult worm antigen re-stimulated splenocytes. (B) IL-10 secretions, measured by ELISA, from adult worm antigen
re-stimulated mesenteric lymph node cells. (C) Foxp3 and CD25 stained CD4+ lymphocytes from peripheral blood, mesenteric lymph nodes (m:LN),
spleen and liver.
doi:10.1371/journal.ppat.1002171.g004
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with anti-IL-10 receptor blockade from week 6 (at the time of PZQ
treatment) to week 8 (time of challenge infection) (Figure 5A).
Significantly fewer worms were recovered at week 15 in mice
treated with anti-IL-10R Ab (35/PZQ/120 + anti-IL-10R),
compared to challenge-only (–/–/120), challenge-only and anti-
IL-10R Ab treatment (–/–/120 + anti-IL-10R) or PZQ-treated
mice with control antibody (35/PZQ/120)(Figure 5B). More-
over, IL-10R blockade during PZQ treatment afforded similar
protection as mice given an irradiated cercariae vaccination
(Irr/–/120), the gold standard for vaccine-induced immunity.
These data indicate that IL-10 impedes the development, or
effector mechanisms, of resistance to re-infection after treatment.
Correlating with increased resistance was a reduction in
circulating neutrophils and an increase in eosinophils
(Figure 5C). Anti-worm Th2 (IL-4 and IL-5), as well as Th1
(IFNc) and Th17 (IL-17A) responses in the spleen (Figure 5D)
and m:LN (Figure 5E) were also elevated in resistant mice.
Correlating with the broadly enhanced T helper responses in anti-
IL-10R Ab treated mice, anti-worm IgG1, IgG2b and IgE isotypes
were also increased (Figure 5F). Anti-schistosomula responses in
the spleen and m:LN were increased following PZQ treatment,
however there was no significant change with the addition of anti-
IL-10R blockade (Figure S3).
Animals treated with anti-IL-10R antibodies had a reduced
frequency of IL-10-producing CD4
+CD44
+CD25
+GITR
+ cells in
the m:LN (Figure 6A) and, to a lesser extent, in the spleen
(Figure 6B), suggesting that IL-10 signaling may promote the
development of IL-10-producing CD4+ T cells. In vitro re-
stimulation with soluble worm antigen also highlighted the
reduced IL-10 responses in anti-IL-10R Ab treated mice
(Figure 6C, D). Irrespective of IL-10R blockade or PZQ
treatment, the frequency of CD4
+CD44
+CD25
+GITR
+Foxp3
+
cells in the spleen or m:LN did not change. Approximately 50% of
GITR
+ cells in the m:LN were also Foxp3
+ and at this time we
cannot completely exclude the role of Foxp3. However, given the
relative unaffected frequencies of Foxp3
+ cells in all experimental
conditions, we consider IL-10 to be the most important inhibitor
of resistance to re-infection. Taken together, these data indicate
that blocking IL-10 signaling during PZQ treatment can
accelerate resistance to re-infection. A wide range of immunolog-
ical parameters were elevated in resistant mice, including anti-
worm Th1, Th2 and Th17 responses as well as a mixed antibody
response. Although a single immunological parameter did not
stand out and correlate with resistance, a mixed response may
indeed be the correlate of protection in this system.
Discussion
In this study we have demonstrated that following PZQ
treatment, IL-10 inhibits the development of protective immunity
to secondary schistosome infection. We observed an elevated anti-
worm immune responses following PZQ treatment alone, however
this failed to confer any protection to a secondary challenge
infection, as previously observed [33]. This was largely due to the
inhibitory effects of IL-10, as blockade of IL-10 combined with
PZQ treatment raised protective immunity from 0% to more than
50% when compared with PZQ treatment alone.
Although still debated, resistance to re-infection in humans
appears to develop following repeated cycles of treatment and re-
exposure. Exposure history can only be estimated, and therefore
the notion that many rounds of re-infection are required before
resistance develops has stood for many years. This has led to an
age-dependent resistance model [17,34], with suggestions that in
addition to several rounds of exposure, puberty and hormones
may also influence resistance to re-infection [35,36]. Recent
evidence however, suggests that resistance is not strictly tied to age,
but rather resistance is a product of exposure and curative
treatment cycles, combined with changes in the immunological
status of the host [18,37]. In a recent study, patients rapidly,
gradually, or never developed resistance to re-infection throughout
a 5-year prospective treatment- re-exposure study. These findings
suggested to us that resistance might be primarily immunologically
determined, rather than being strictly dependent on age and
exposure history.
Following PZQ treatment, S. mansoni-infected patients have
been shown to exhibit elevated IL-4, IL-5 and IL-13 [19,20]
responses and increased numbers of circulating eosinophils [38].
Colley and colleagues [30] have also observed elevated anti-worm
responses in schistosome infected Egyptians up to 2-years
following PZQ treatment. We observed a similar increase in
parasite-specific T cell proliferation, cytokine secretion, and
antibody production in infected mice following PZQ treatment.
However, despite exhibiting significantly elevated anti-worm
responses, the mice remained fully susceptible to a secondary
challenge infection. Mitchell and colleagues also investigated this
phenomenon and found that immunizing mice with adult worm
antigens in combination with PZQ treatment was still incapable of
conferring protection from re-infection [39]. A large proportion of
drug treated patients also remain highly susceptible to reinfection
[30]. The mechanism behind the failure to generate a protective
recall response following a cleared primary infection remains
unclear. The current hypothesis from human studies suggests that
several treatment and re-exposure cycles are needed, which
triggers the release of worm antigens[40] that repeatedly prime
and boost the immune response, analogous to the immunity
achieved following multiple vaccinations. Several rounds of
treatment and re-infection likely mimic and accelerate the
acquisition of acquired immunity, which would otherwise take
years to develop [15]. So, the question remains - why do infected
and treated hosts develop increased anti-worm immune responses
but remain susceptible to re-infection?
We designed experiments to avoid the influence of egg-induced
liver inflammation when non-specific resistance can develop[41].
The cost of such experimental design however, does pose a
limitation on translating our findings to human infections, where
diagnosis is often based upon egg detection. We hypothesized that
opposing immunoregulatory responses were developing in
parallel with the effector response and inhibiting the activation
of effective anti-worm immunity. In support of this hypothesis, we
observed a marked increase in IL-10 production and identified a
population of putative regulatory T cells (CD4+CD44+CD25+
GITR+IL-10gfp+) following PZQ treatment. Although we did
not observe any change in Foxp3+ cells following PZQ treatment,
we cannot rule out the possibility that the IL-10-producing T cells
are a subset of Foxp3+ natural regulatory T cells or recently
activated effector T cells. An increased IL-10 response has also
been observed in PZQ-treated humans, which similarly paralleled
an elevated anti-worm Th2 response [20]. Longitudinal immu-
nological studies conducted in schistosome endemic regions have
also strongly implicated a negative regulatory role for IL-10 in the
development of resistance to re-infection in humans [42,43].
Despite developing enhanced parasite-specific IL-5 responses
following treatment, Van den Bigelaar and colleagues identified a
concurrent increase in parasite-specific IL-10, and proposed that
IL-10 was a major risk factor for re-infection. Similarly, Leenstra
and colleagues [43] found that elevated IL-10 predicted a
decrease in time to re-infection with several reports describing
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PLoS Pathogens | www.plospathogens.org 8 August 2011 | Volume 7 | Issue 8 | e1002171Figure 5. IL-10-blockade establishes resistance to re-infection. C57BL/6 mice were infected as in Figure 2, with a sub group of mice treated
with anti-IL-10RAb (1 mg/mouse at the start of PZQ treatment- wk6, wk7 and wk 8). Data shown are mean 6 SEM from one of 3 experiments, with 7
mice per group. (A) Experimental model diagram. (B) Total worm numbers at week 15. (C) Circulating eosinophils and poly-morphonuclear cells. (D)
Cytokine secretions, measured by ELISA, from adult worm antigen re-stimulated splenocytes. (E) Cytokine secretions, measured by ELISA, from adult
worm antigen re-stimulated mesenteric lymph node cells. (F) Anti-worm antibody responses, measured by ELISA.
doi:10.1371/journal.ppat.1002171.g005
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PLoS Pathogens | www.plospathogens.org 9 August 2011 | Volume 7 | Issue 8 | e1002171Figure 6. IL-10 blockade, reduces IL-10 producing cells, IL-10 secretion from spleen and mesenteric lymph nodes, with unchanged
Foxp3+ cells. C57BL/6 or Foxp3
gfp-reporter mice were infected and treated, as in Figure 5, with cells recovered at necropsy. Data shown are mean 6
SEM from one of 2 experiments, with 5 mice per group. (A) GITR
+IL-10gfp
+ mesenteric lymph nodes cells within the CD4
+CD44
+CD25
+ population. (B)
GITR
+IL-10gfp
+ splenocytes within the CD4
+CD44
+CD25
+ population. (C) IL-10 secretions, measured by ELISA, from adult worm antigen re-stimulated.
mesenteric lymph node cells. (D) IL-10 secretions, measured by ELISA, from adult worm antigen re-stimulated splenocytes. (E) GITR
+Foxp3
+
mesenteric lymph nodes cells within the CD4
+CD44
+CD25
+ population, using Foxp3
gfp reporter mice. (F) GITR
+Foxp3
+ splenocytes within the
CD4
+CD44
+CD25
+ population, using Foxp3
gfp reporter mice.
doi:10.1371/journal.ppat.1002171.g006
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haematobium [45] infection intensity. These data support the
concept that IL-10 functions as an important regulator of
protective immunity and resistance to re-infection, which is
consistent with its well established role as a suppressor of
immunopathology during infection with S. mansoni
[46,47,48,49,50,51,52,53,54,55,56,57]. IL-10 has also been
shown to suppress S. manoni egg and worm-specific human
PBMC proliferation and cytokine production in vitro
[58,59,60,61]. However, whether IL-10 obstructs the develop-
ment of resistance to re-infection remained unclear.
We hypothesized that IL-10 was suppressing both anti-worm
and anti-larval responses and was responsible for the failure to
develop resistance [62,63]. We tested the impact of IL-10 in the
development of resistance in a therapeutic model, combining anti-
IL-10R Ab treatment with PZQ treatment. IL-10-blockade during
PZQ treatment further increased anti-worm immune responses,
and afforded significant protection from re-infection. Anti-larval
responses were not directly measured in this study and although
there may be cross-reactivity between adult and larval epitopes,
increased resistance correlated with increased anti-adult immune
parameters. The level of protection following combined PZQ
treatment and IL-10 blockade equaled that achieved by the
irradiated cercariae vaccination, which serves as the ‘gold
standard’ for vaccine induced immunity. This observation is
supported from other studies suggesting that immunoregulatory
responses, in particular IL-10, can actively impede the develop-
ment of immunity to infection either naturally [64,65,66,67], or
following vaccination [68,69,70,71,72,73]. Whether the Gluco-
corticoid-induced TNFR-related protein (GITR), which is ex-
pressed on these cells, functions as a proliferative [74], cytokine
enhancing [75], or inhibitory receptor is currently unknown.
Nevertheless, it is clear from our studies that IL-10 expressed in
GITR
+CD4
+ T cells and potentially other cell types[53], restricts
the type and magnitude of the protective immune response
following treatment with PZQ. Thus, combining IL-10R blockade
with chemotherapy may accelerate the development of protective
immunity in otherwise permissive hosts.
It has previously been reported that resistance to re-infection in
mice can be achieved through physiological means, as mentioned
above. Wilson and colleagues [76] demonstrated that the
development of anastomoses precludes parasite maturation and
migration, with reduced adult worm establishment. Although we
cannot rule this out in our system, we believe there to be an
immunological mechanism of resistance following IL-10R
blockade. Many immunological correlates of resistance to re-
infection in humans have been reported including IL-5 [17,77]
and eosinophilia [78,79], mast cells [80] and IFNc [77]. Antibody
responses, in particular anti-IgE adult worm antibodies [17,78,
81,82,83,84,85,86] and CD23
hi B cell responses [87] have also
been described. In our studies, blockade of IL-10 in conjunction
with PZQ treatment led to an increase in eosinophilia and adult
worm-specific IL-4, IL-5, IFNc and IL-17A. Anti-worm-specific
IgG1, IgG2b and IgE were also elevated, providing evidence of
an exaggerated but mixed cytokine profile, which was shown
previously to improve vaccine-induced immunity to S. mansoni by
boosting both humoral and cell-mediated immune responses
against the parasite[62]. Whether larval stages (cercariae, early
and late stage schistosomula) are the targets of protective
immunity with anti-IL-10R mAb + PZQ treatment are currently
unknown. Greater protection from schistosome infection has
been observed in IL-10-deficient mice given an irradiated
cercariae vaccine [62]. In this scenario a mixed Th1/Th2
response was observed. Furthermore, whether a single immuno-
dominant antigen is responsible for the protection is also not
known. Conceivably, IL-10 blockade may allow a wider
repertoire of antigens with greater magnitude and diversity.
The impact of IL-10 on antigen repertoire and different classes of
immune responses with respect to resistance to re-infection
should be the subject of future studies if this regimen is to move
successfully into patients.
In conclusion, this study demonstrates that IL-10, derived
predominantly from CD4+ lymphocytes, hampers the develop-
ment of critical effector mechanisms that mediate resistance to
schistosome infection following treatment. These observations
suggest that immunomodulators delivered in combination with
PZQ treatment may be required to generate the robust and mixed
humoral and cell-mediated immune response that is required to
prevent reinfection with schistosomes.
Supporting Information
Figure S1 Elevated CD4
+IL-10gfp
+ cells, with minor
increases in B220
+IL-10gfp
+ and CD8
+IL-10gfp
+ cells in
PZQ-treated mice. C57BL/6 mice were infected as in Figure 2,
with cells isolated from the spleen, stained as in methods and
analyzed with FlowJo software. Data shown are mean 6 SEM
from one of 2 experiments, with 5 mice per group.
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Figure S2 Elevated CD4
+CD44
+CD25
+GITR
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Figure S3 Anti-Schistosomula cytokine responses with-
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